A drugmaker spun out of Imperial College and the Crick Institute has secured one of Europe’s largest-ever early stage fundraising for a biotech,with £90 million backing for its pioneering cancer treatment.
Myricx Bio is working on drugs designed to destroy cancer cells - initially in breast and gastric tumours - with ‘precision oncology’.
